Verschluss des Herzohrs zur Schlaganfallprophylaxe

Abstract

90 % of thromboembolisms in patients with non-valvular atrial fibrillation are thought to arise from the left atrial appendage (LAA). Anticoagulation with Vitamin-K-antagonist is the current gold standard in stroke prevention. In recent years, several interventional devices have been developed to exclude the LAA and thus to minimize the risk of stroke. The present article reviews the problem, the concept, the technique and clinical efficacy of interventional LAA exclusion.

Literatur

• 1 Lloyd-Jones D, Adams R J, Brown T M. et al . Heart disease and stroke statistics – 2010 update: a report from the American Heart Association.  Circulation. 2010;  121 e46-e215
• 2 Fuster V, Ryden L E, Cannom D S. et al . ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary.  Eur Heart J. 2006;  27 1979-2030
• 3 Hart R G, Pearce L A, Aguilar M I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.  Ann Intern Med. 2007;  146 857-867
• 4 Fang M C, Stafford R S, Ruskin J N, Singer D E. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation.  Arch Intern Med. 2004;  164 55-60
• 5 Reynolds M R, Shah J, Essebag V. et al . Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry.  Am J Cardiol. 2006;  97 538-543
• 6 Choudhry N K, Anderson G M, Laupacis A. et al . Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis.  BMJ. 2006;  332 141-145
• 7 Choudhry N K, Soumerai S B, Normand S L. et al . Warfarin prescribing in atrial fibrillation: the impact of physician, patient, and hospital characteristics.  Am J Med. 2006;  119 607-615
• 8 Gottlieb L K, Salem-Schatz S. Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice?.  Arch Intern Med. 1994;  154 1945-1953
• 9 Johnson W D, Ganjoo A K, Stone C D. et al . The left atrial appendage: our most lethal human attachment! Surgical implications.  Eur J Cardiothorac Surg. 2000;  17 718-22
• 10 Al-Saady N M, Obel O A, Camm A J. Left atrial appendage: structure, function, and role in thromboembolism.  Heart. 1999;  82 547-554
• 11 Okura H, Inoue H, Tomon M. et al . Is the left atrium the only embolic source in ischemic stroke patients with nonvalvular atrial fibrillation?.  Am J Cardiol. 1999;  84 1259-1261
• 12 Healey J S, Crystal E, Lamy A. et al . Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke.  Am Heart J. 2005;  150 288-293
• 13 Ho I C, Neuzil P, Mraz T. et al . Use of intracardiac echocardiography to guide implantation of a left atrial appendage occlusion device (PLAATO).  Heart Rhythm. 2007;  4 567-571
• 14 Ostermayer S H, Reisman M, Kramer P H. et al . Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials.  J Am Coll Cardiol. 2005;  46 9-14
• 15 Block P C, Burstein S, Casale P N. et al . Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study.  JACC Cardiovasc Interv. 2009;  2 594-600
• 16 Sick P B, Schuler G, Hauptmann K E. et al . Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation.  J Am Coll Cardiol. 2007;  49 1490-1495
• 17 Holmes D R, Reddy V Y, Turi Z G. et al . Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.  Lancet. 2009;  374 534-542
• 18 Schulman S, Kearon C, Kakkar A K. et al . Dabigatran versus warfarin in the treatment of acute venous thromboembolism.  N Engl J Med. 2009;  361 2342-252